Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis

Kristian B Filion, Dan Chateau, Laura E Targownik, Andrea Gershon, Madeleine Durand, Hala Tamim, Gary F Teare, Pietro Ravani, Pierre Ernst, Colin R Dormuth, CNODES Investigators, Samy Suissa, Colin Dormuth, Brenda Hemmelgarn, Gary Teare, Patricia Martens, Patricia Caetano, David Henry, Michael Paterson, Jacques Lelorier, Adrian Levy, Pierre Ernst, Robert Platt, Ingrid Sketris, Kristian B Filion, Dan Chateau, Laura E Targownik, Andrea Gershon, Madeleine Durand, Hala Tamim, Gary F Teare, Pietro Ravani, Pierre Ernst, Colin R Dormuth, CNODES Investigators, Samy Suissa, Colin Dormuth, Brenda Hemmelgarn, Gary Teare, Patricia Martens, Patricia Caetano, David Henry, Michael Paterson, Jacques Lelorier, Adrian Levy, Pierre Ernst, Robert Platt, Ingrid Sketris

Abstract

Objective: Previous observational studies suggest that the use of proton pump inhibitors (PPIs) may increase the risk of hospitalisation for community-acquired pneumonia (HCAP). However, the potential presence of confounding and protopathic biases limits the conclusions that can be drawn from these studies. Our objective was, therefore, to examine the risk of HCAP with PPIs prescribed prophylactically in new users of non-steroidal anti-inflammatory drugs (NSAIDs).

Design: We formed eight restricted cohorts of new users of NSAIDs, aged ≥40 years, using a common protocol in eight databases (Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, US MarketScan and the UK's General Practice Research Database (GPRD)). This specific patient population was studied to minimise bias due to unmeasured confounders. High-dimensional propensity scores were used to estimate site-specific adjusted ORs (aORs) for HCAP at 6 months in PPI patients compared with unexposed patients. Fixed-effects meta-analytic models were used to estimate overall effects across databases.

Results: Of the 4,238,504 new users of NSAIDs, 2.3% also started a PPI. The cumulative 6-month incidence of HCAP was 0.17% among patients prescribed PPIs and 0.12% in unexposed patients. After adjustment, PPIs were not associated with an increased risk of HCAP (aOR=1.05; 95% CI 0.89 to 1.25). Histamine-2 receptor antagonists yielded similar results (aOR=0.95, 95% CI 0.75 to 1.21).

Conclusions: Our study does not support the proposition of a pharmacological effect of gastric acid suppressors on the risk of HCAP.

Keywords: Epidemiology; Gastroesophageal Reflux Disease; Meta-Analysis; Proton Pump Inhibition.

Figures

Figure 1
Figure 1
Forest plot of the association between the use of proton pump inhibitors (PPIs) and the 6-month cumulative incidence of hospitalisation for community-acquired pneumonia in a restricted cohort of new users of non-steroidal anti-inflammatory drugs (NSAIDs). Analyses were adjusted for age, sex, previous non-hospitalised pneumonia, prescription of  PPIs, histamine-2 receptor antagonists and NSAIDs  in the 7–12 months prior to cohort entry, and high-dimensional propensity score decile. GPRD,  General Practice Research Database.
Figure 2
Figure 2
Forest plot of the association between the use of histamine-2 receptor antagonists and the 6-month cumulative incidence of hospitalisation for community-acquired pneumonia in a restricted cohort of new users of non-steroidal anti-inflammatory drugs (NSAIDs). Analyses were adjusted for age, sex, previous non-hospitalised pneumonia, prescription of proton pump inhibitors, histamine-2 receptor antagonists and NSAIDs in the 7–12 months prior to cohort entry, and high-dimensional propensity score decile. GPRD, General Practice Research Database.

References

    1. Katz MH. Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 2010;170:747–8
    1. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 2009;104(Suppl 2):S27–32
    1. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310–19
    1. Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med 2009;4:115–23
    1. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997;113:755–60
    1. Hermos JA, Young MM, Fonda JR, et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012;54:33–42
    1. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007;167:950–5
    1. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533–49
    1. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 2011;70:818–22
    1. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009;29:481–96
    1. Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med 2012;6:134–40
    1. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915–20
    1. Skull SA, Andrews RM, Byrnes GB, et al. ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged > or=65 years. Epidemiol Infect 2008;136:232–40
    1. Szklo M, Nieto FJ. Epidemiology: beyond the basics. Sudbury, MA: Aspen Publishers, 1999
    1. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512–22
    1. Egger M, Smith GD, Altman DG. Systematic reviews in healthcare: meta-analysis in context. 2nd edn London: BMJ Publishing Group, 2001
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58
    1. Tett SE, Sketris I, Cooke C, et al. Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. Pharmacoepidemiol Drug Saf Published Online First: 4 Apr 2013. doi: 10.1002/pds.3442
    1. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–60
    1. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008;149:391–8
    1. Myles PR, Hubbard RB, McKeever TM, et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009;18:269–75
    1. Rodriguez LA, Ruigomez A, Wallander MA, et al. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009;20:800–6
    1. Roughead EE, Ramsay EN, Pratt NL, et al. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust 2009;190:114–16
    1. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165–77
    1. Dublin S, Walker RL, Jackson ML, et al. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study. Pharmacoepidemiol Drug Saf 2010;19:792–802
    1. Rascon-Aguilar IE, Pamer M, Wludyka P, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest 2006;130:1096–101
    1. Metheny NA, Chang YH, Ye JS, et al. Pepsin as a marker for pulmonary aspiration. Am J Crit Care 2002;11:150–4
    1. Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013;28:223–30
    1. Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf 2008;31:627–36
    1. McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):18–22
    1. Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System–a national resource for evidence development. N Engl J Med 2011;364:498–9
    1. Roos LL, Gupta S, Soodeen RA, et al. Data quality in an information-rich environment: Canada as an example. Can J Aging 2005;24(Suppl 1):153–70
    1. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128–36
    1. Canadian Institute for Health Information CIHI data quality study of the 2006–2007 Discharge Abstract Database. Ottawa, Canadian Institute for Health Information, 2009, 12-5-2013
    1. Lindenauer PK, Lagu T, Shieh MS, et al. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003–2009. JAMA 2012;307:1405–13

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera